Creabilis hires chief medical officer

Dr David Roblin joins the firm after holding leading roles at Pfizer and Bayer

Creabilis, a clinical stage European biotechnology company focused on dermatology, inflammation and pain, has appointed David Roblin as chief medical officer.

Roblin has gained extensive experience in the pharmaceutical industry in a career spanning more than 15 years. He has held leadership roles at Pfizer and Bayer across a range of therapy areas in research, development and commercial roles.

At Pfizer, Roblin was most recently senior vice president, head of research and site head for European r&d. Before this, he was head of anti-infectives at Bayer Medical Affairs.

In addition Roblin has chaired the research director’s group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and was a co-founder of the Innovative Medicines Initiative, a US$2bn public-private partnership with the European Commission.

You may also like

Finance

Creabilis establishes UK operation

Location in Kent broadens the county’s links with the pharma industry
Pharmaceutical

Boehringer Ingelheim adds antibody-based cancer drug from AimedBio to its portfolio

The two have signed a licence agreement, which will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with the new asset expected to enter first-in-human studies next year
Microbiology

Balchem to showcase new line of probiotic stabilising excipients at SupplySide Global

The company will debut its new excipient portfolio, StabiliPro, at SupplySide Global 2025 in Las Vegas
Pharmaceutical

ProSpecBio launches CHO cell-derived Activin-A recombinant protein to advance inflammation and brain injury research

ProSpecBio has introduced a highly purified, CHO cell-derived recombinant Activin-A protein, enabling researchers worldwide to explore its therapeutic potential in inflammation, brain injury and regenerative medicine
Pharmaceutical

Asahi Kasei expands Sonanos portfolio with next-generation excipients for injectable drug formulation

Asahi Kasei has introduced two new speciality grades in its Sonanos excipient line designed to enhance sustained release and solubility in injectable drugs and plans GMP-compliant production by 2027
Ingredients

Roquette launches KLEPTOSE Crysmeb methyl-beta-cyclodextrin for oral and parenteral formulations

The addition of the novel pharmaceutical excipient boosts the company's already extensive cyclodextrins portfolio
Manufacturing

Rentschler Biopharma expands services in Japan and South Korea ahead of BioProcess International Asia

Rentschler Biopharma will showcase its Rentschler Expression Platform and Development Services at BioProcess International Asia in Kyoto, underscoring its commitment to supporting biopharma partners across Japan and South Korea
Subscribe now